Accro Bioscience (Suzhou) Limited, a leader in China's small molecule drug development, recently closed its Series B fundraising, raising over $50 million and surpassing its initial fundraising target. The round was led by Hongtai Aplus, with participation from South China Venture Capital, Shenzhen Capital Group, ORIZA HOLDINGS, GF Xinde Investment, and Sanhua Holding Group.

CEC Capital Group acted as the exclusive financial advisor to Accro Bioscience in this transaction.

The proceeds from this financing will be primarily used to advance the clinical trials and preclinical development of multiple projects in Accro Bioscience's research pipeline, as well as to expand international business collaborations